Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?

Annals of Oncology

Volumn 16, Issue 1, 2005, Pages 47-50

  Crawford, S Michael ^a   Peace, J ^a  

^a AIREDALE GENERAL HOSPITAL   (United Kingdom)

Author keywords

CA125; Carcinoma of the ovary; Prognosis; Response to chemotherapy; Tumour markers

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; PACLITAXEL; TUMOR MARKER;

ARTICLE; BIOCHEMISTRY; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NONBIOLOGICAL MODEL; OVARY CARCINOMA; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TIME; TREATMENT OUTCOME;

EID: 12344319318     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi012     Document Type: Article

References (10)

1. Meyer T, Rustin GJS. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000; 82: 1535-1538.
2. Rustin GJS, Marples M, Nelstrop AE, Meyer T. Use of CA125 to define the progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001; 19: 4054-4057.
3. Fayers PM, Rustin G, Wood M et al. The prognostic value of serum CA125 in patients with advanced ovarian cancer: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynaecol Oncol 1993; 3: 286-292.
4. Vergote I, Rustin GJS, Eisenhauer EA et al. for the Gynecologic Cancer Intergroup. New Guidelines to evaluate the response to treatment in solid tumours (ovarian cancer). J Natl Cancer Inst 2000; 92: 1534-1535.
5. Epiney M, Bertossa C, Weil A et al. CA125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 2000; 15: 1261-1265.
6. Bese T, Demirkiran F, Arvas M et al. What should be the cut-off level of serum CA125 to evaluate the disease status before second-look laparotomy in epithelial ovarian carcinoma? Int J Gynecol Cancer 1997; 7: 42-45.
7. Moss C, Kaye SB. Ovarian cancer: progress and continuing controversies in management. Eur J Cancer 2002; 38: 1701-1707.
8. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 months versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465.
9. Skates SJ, Xu F-J, Yi Y-H et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995; 76: 2004-2010.
10. Crawford SM, Paul J, Reed NS et al. and Scottish Gynaecological Cancer Trials Group. The prognostic significance of the CA125 nadir in patients that achieve a CA125 response. Proc ASCO J Clin Oncol 2004; 22 (Suppl 14S): 449s (Abstr 5001).